Checkpoint Inhibitors and Immuno-Oncology

30 Oct, 2017

The Fight Against Cancer: Neoantigens, Tumor Escape and the Tumor Microenvironment

The Fight Against Cancer: Neoantigens, Tumor Escape and the Tumor Microenvironment A conversation with JOHN WEST, CEO of Personalis, Inc. in Menlo, Park, California Nature, October 26, 2017 Tumours may be initiated by mutations in their driver genes, but their clinical outcomes are strongly influenced by the battle between [...]

30 Oct, 2017

Getting cancer vaccines right: Key challenges and solutions for neoantigen identification

Getting cancer vaccines right: Key challenges and solutions for neoantigen identification A conversation with Richard Chen, MD, CSO of Personalis, Inc. in Menlo, Park, California FierceBiotech, June 26, 2017 The promise of neoantigen-based cancer vaccines Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer. The development of [...]

23 Jan, 2017

Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research

GenomeWeb: Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research This GenomeWeb seminar outlines a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. Presenters: Richard Chen, MD and Michael James Clark, PhD More Info: NGS is increasingly being used to support cancer clinical trials, translational [...]

7 Dec, 2016

Tumor Characterization Solutions for Clinical Trials, Cancer Research & Immuno-Oncology

Tumor Characterization Solutions for Clinical Trials, Cancer Research & Immuno-Oncology This presentation covers comprehensive tumor characterization solutions for clinical trials, cancer research and immune-oncology, including: specific challenges in sequencing and analyzing tumors for neoantigen identification; key differentiators of the ACE ImmunoID as compared to standard NGS offerings; and a review of the technical [...]

Go to Top